03.19.21
The COVID-19 vaccine distribution has been a massive effort. While much of the focus is on the vaccines themselves, much more goes into the actual doses, from transportation logistics to syringes and more.
The actual vials that carry the medicine are a critical component, and SCHOTT’s pharmaceutical packaging business unit has been the major player there. Thwe company noted that approximately 90% of approved vaccines rely on SCHOTT vials.
Schott recently passed an impressive milestone, having delivered enough vials to provide more than 1 billion doses of COVID-19 vaccines. The company said it is well on the way to delivering vials for more than 2 billion vaccine doses through 2021.
SCHOTT’s global manufacturing footprint includes five sites dedicated to the manufacture of type-1 borosilicate glass tubes and another 16 plants converting the tubes into vials.
“The reaction of the pharmaceutical community to COVID-19 is a testament to the power of scientific progress,” said Dr. Frank Heinricht, CEO of SCHOTT AG. “In just under a year, all previous records for vaccine development have been shattered by not just one, but several research groups. The entire industry is successfully working together to ensure an adequate supply.”
The success of the COVID-19 response is supported by the company’s multi-year, $1 billion global investment in pharmaceutical glass and packaging facilities announced early 2019 in response to rising worldwide demand for safer drug packaging.
The actual vials that carry the medicine are a critical component, and SCHOTT’s pharmaceutical packaging business unit has been the major player there. Thwe company noted that approximately 90% of approved vaccines rely on SCHOTT vials.
Schott recently passed an impressive milestone, having delivered enough vials to provide more than 1 billion doses of COVID-19 vaccines. The company said it is well on the way to delivering vials for more than 2 billion vaccine doses through 2021.
SCHOTT’s global manufacturing footprint includes five sites dedicated to the manufacture of type-1 borosilicate glass tubes and another 16 plants converting the tubes into vials.
“The reaction of the pharmaceutical community to COVID-19 is a testament to the power of scientific progress,” said Dr. Frank Heinricht, CEO of SCHOTT AG. “In just under a year, all previous records for vaccine development have been shattered by not just one, but several research groups. The entire industry is successfully working together to ensure an adequate supply.”
The success of the COVID-19 response is supported by the company’s multi-year, $1 billion global investment in pharmaceutical glass and packaging facilities announced early 2019 in response to rising worldwide demand for safer drug packaging.